Open AccessWhere are we with bladder preservation for muscle-invasive bladder cancer in 2017?
Author(s) -
Woodson Smelser,
Marcus Austenfeld,
Jeffrey M. Holzbeierlein,
Eugene Kang Lee
Publication year - 2017
Publication title -
indian journal of urology/indian journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.333
H-Index - 30
eISSN - 1998-3824
pISSN - 0970-1591
DOI - 10.4103/iju.iju_279_16
Subject(s) - medicine , cystectomy , bladder cancer , gold standard (test) , cancer , modalities , randomized controlled trial , disease , urology , surgery , social science , sociology
In 2017, neoadjuvant, cisplatin-based chemotherapy followed by radical cystectomy (RC) is considered the gold standard therapy for muscle-invasive bladder based on randomized controlled trials. Across all tumor stages, this approach has been associated with the highest rates of disease-specific survival. However, RC is one of the most challenging procedures performed by urologic surgeons and carries with it significant risks of complications, hospital readmission, and even a small risk of mortality, in addition to lifestyle changes that can have long-term effects on well-being. For these reasons, bladder-sparing approaches are utilized in some highly selected patients. We reviewed the most recent evidence for bladder-sparing modalities for muscle-invasive urothelial bladder cancer and summarize those findings in this review article.